Meitav Dash Investments Ltd. acquired a new position in Gamida Cell Ltd (NASDAQ:GMDA) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 219,717 shares of the company’s stock, valued at approximately $1,004,000. Meitav Dash Investments Ltd. owned 0.91% of Gamida Cell as of its most recent filing with the Securities & Exchange Commission.
Separately, UBS Group AG purchased a new position in shares of Gamida Cell in the fourth quarter valued at $28,000. Institutional investors own 21.76% of the company’s stock.
Several research firms have recently weighed in on GMDA. Needham & Company LLC started coverage on Gamida Cell in a research report on Tuesday, August 11th. They set a “buy” rating and a $17.00 target price for the company. Piper Sandler initiated coverage on Gamida Cell in a research note on Monday, May 25th. They issued an “overweight” rating and a $13.00 target price on the stock. HC Wainwright restated a “buy” rating on shares of Gamida Cell in a research note on Thursday, August 13th. Oppenheimer lifted their target price on Gamida Cell from $18.00 to $20.00 and gave the stock an “outperform” rating in a report on Tuesday, May 12th. Finally, Evercore ISI assumed coverage on Gamida Cell in a report on Tuesday, June 30th. They issued an “outperform” rating for the company. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $15.00.
GMDA traded down $0.09 during midday trading on Thursday, reaching $4.21. 1,213 shares of the company’s stock were exchanged, compared to its average volume of 216,472. The firm has a market capitalization of $105.12 million, a price-to-earnings ratio of -2.94 and a beta of 1.94. The company has a quick ratio of 6.69, a current ratio of 6.69 and a debt-to-equity ratio of 0.08. Gamida Cell Ltd has a one year low of $2.60 and a one year high of $7.70. The business has a 50-day simple moving average of $4.30 and a two-hundred day simple moving average of $4.38.
Gamida Cell (NASDAQ:GMDA) last posted its earnings results on Tuesday, August 11th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.11). As a group, research analysts anticipate that Gamida Cell Ltd will post -1.29 EPS for the current fiscal year.
About Gamida Cell
Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II studies in patients with severe aplastic anemia.
Further Reading: Depreciation
Want to see what other hedge funds are holding GMDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gamida Cell Ltd (NASDAQ:GMDA).
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.